Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nintedanib
Drug ID BADD_D02470
Description Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014.[L8453] Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function.[A185237] As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.[L8459]
Indications and Usage Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
Marketing Status Not Available
ATC Code L01EX09
DrugBank ID DB09079
KEGG ID D10481
MeSH ID C530716
PubChem ID 135423438
TTD Drug ID D09HNV
NDC Product Code 55361-0021; 0597-0145; 66499-0061; 55361-0020; 0597-0143
Synonyms nintedanib | Nintedanib esylate | Ofev | Vargatef | BIBF 1120 | BIBF1120 | BIBF-1120
Chemical Information
Molecular Formula C31H33N5O4
CAS Registry Number 656247-17-5
SMILES CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Back pain15.03.04.005--
Bladder cancer16.08.01.001; 20.03.04.001--Not Available
Blindness17.17.01.003; 06.02.02.001--Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Blood albumin decreased13.09.01.0010.000533%Not Available
Blood bilirubin increased13.03.01.0080.001598%
Blood creatinine increased13.13.01.004--
Blood glucose decreased13.02.02.0010.000799%Not Available
Blood glucose increased13.02.02.002--Not Available
Blood magnesium decreased13.11.01.0080.000533%Not Available
Blood pressure increased13.14.03.0050.003730%Not Available
Bronchiectasis22.03.02.0050.000533%Not Available
Bronchitis11.01.09.001; 22.07.01.0010.003197%
Bronchitis chronic22.03.01.0190.000533%Not Available
Bronchopulmonary aspergillosis22.07.08.001; 11.03.01.0020.000208%Not Available
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Cachexia14.03.02.001; 08.01.01.009; 16.32.03.0110.000139%Not Available
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.0010.001459%
Cardiac failure congestive02.05.01.002--Not Available
Cardio-respiratory arrest02.03.04.002; 22.02.06.0070.000486%Not Available
Cardiogenic shock24.06.02.006; 02.05.01.0030.000139%Not Available
Cardiomyopathy02.04.01.001--Not Available
Cardiovascular disorder24.03.02.009; 02.01.01.001--Not Available
Cellulitis11.02.01.001; 23.09.01.001--Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.0030.000764%Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.003197%Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.0070.009058%
Chest discomfort02.02.02.009; 22.02.08.001; 08.01.08.019--Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.0110.009058%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 14 Pages